Subscribe Now Subscribe Today
Science Alert
 
Blue
   
Curve Top
International Journal of Pharmacology
  Year: 2020 | Volume: 16 | Issue: 5 | Page No.: 398-406
DOI: 10.3923/ijp.2020.398.406
 
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Prevention of Metabolic, Redox and Lipid Biosynthesis Alterations by Visnagin in High Cholesterol-Fed Rats

Fakhria Al-Joufi

Abstract:
Background and Objective: Hypercholesterolemia is a risk factor for many cardiac and hepatic disorders. Visnagin (VIS) is a coumarin with an anti-inflammatory effect; however, its anti-dyslipidemia activity has not been investigated. This study evaluated the effect of VIS on hypercholesterolemia, oxidative stress and inflammatory response in high cholesterol diet (HCD)-fed rats. Materials and Methods: Rats received an HCD and VIS (30 and 60 mg kg1) for 10 weeks and samples were harvested. Results: HCD increased serum cholesterol, triglycerides, LDL, VLDL, transaminases, CK-MB and pro-inflammatory cytokines and decreased HDL-cholesterol. VIS ameliorated serum lipids, liver and heart functions and cardiovascular risk indices in HCD-fed rats. Besides, VIS suppressed hepatic lipid peroxidation and increased the levels of cellular antioxidants. The effects of VIS were associated with increased hepatic LDL receptor (LDLR) and decreased HMG-CoA reductase (HMGR) expression. Conclusion: These results demonstrate the anti-hypercholesterolemic activity of VIS in rats. VIS ameliorated serum lipids, inflammation, liver and heart function and oxidative stress and modulated hepatic HMGR and LDLR. Therefore, VIS is a promising candidate for the treatment of hypercholesterolemia.
PDF Fulltext XML References Citation Report Citation
How to cite this article:

Fakhria Al-Joufi , 2020. Prevention of Metabolic, Redox and Lipid Biosynthesis Alterations by Visnagin in High Cholesterol-Fed Rats. International Journal of Pharmacology, 16: 398-406.

DOI: 10.3923/ijp.2020.398.406

URL: https://scialert.net/abstract/?doi=ijp.2020.398.406

COMMENT ON THIS PAPER
 
 
 

 

 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 

Curve Bottom